Organic compounds -- part of the class 532-570 series – Organic compounds – Heavy metal containing
Reexamination Certificate
2008-07-29
2008-07-29
Gonzale, Porfirio Nazario (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heavy metal containing
C556S076000, C514S504000
Reexamination Certificate
active
07405314
ABSTRACT:
The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.
REFERENCES:
patent: 6191123 (2001-02-01), Uckun et al.
patent: 6482815 (2002-11-01), Uckun et al.
patent: 6482816 (2002-11-01), Uckun et al.
patent: 6911471 (2005-06-01), Zingaro et al.
patent: 2002/0013371 (2002-01-01), Warrell et al.
patent: 2002/0183385 (2002-12-01), Ellison et al.
patent: 2003/0176359 (2003-09-01), Neuwelt et al.
patent: 2004/0028750 (2004-02-01), Lu
patent: 2005/0131062 (2005-06-01), Zingaro et al.
patent: 1002537 (1998-10-01), None
patent: 188 971 (1966-11-01), None
patent: WO-99/24029 (1998-11-01), None
patent: WO-03/057012 (2003-07-01), None
patent: WO-2006/020048 (2006-02-01), None
Fatouros, et al., “Preparation and properties of arsonolipid containing liposomes,” Chemistry and Physics of Lipids, 109:75-89 (2001).
American Conference of Governmental Industrial Hygienists, Inc. (ACGIH). Arsenic and soluble compounds, including arsine. Documentation of the Threshold Limit Values and Biological Exposure Indices, sixth edition, 1991.
Aslanidis, et al., “Methylarsino-substituted hydroxy carboxylate esters,” Chemiker-Zeitung, 112(4):125-127 (1988).
Bachleitner-Hofmann et al., “Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia,” Br. J. Haematol., 112(3):783-786 (2001).
Beckermann, “Determination of monovethylarsonic acid and dimethylarsinic acid by derivatization with thioglycolic acid methyl ester and gas-liquid chromatographic separation,” Analytica Chimica Acta, 135(1):77-84 (1982).
Beliles, “The Metals,” InPatty's Industrial Hygiene and Toxicology, fourth editionG.D. Clayton and F.E. Clayton, eds. John Wiley & Sons, Inc.: New York. pp. 1913-1925 (1994).
Calleja and Warrell, “Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia,” Curr. Oncol. Rep., 2:519-523 (2000).
Chen, et al., “6-thio-and-seleno-alpha-D-glucose esters of dimethylarsinous acid,” Carb. Res. 50:53-62 (1976).
Cullen, et al., “The metabolism of methylarsine oxide and sulfide,” Applied Organometallic Chemistry, 3(1):71-78 (1989).
Cuzick, et al., “Medicinal arsenic and internal malignancies,” Br. J. Cancer, 45:904-911 (1982).
Emran, et al., “Synthesis and biodistribution of radioarsenic labeled dimethylarsinothiols: derivatives of pennicillamine and mercaptoethanol,” International Journal of Nuclear Medicine and Biology, 11(3-4):259-261 (1984).
Forkner and McNair-Scott, “Arsenic as a therapeutic agent in chronic myeloid leukemia,” JAMA, 97(1):3-6 (1931).
Geissler, et al., “In vivo effects of arsenic trioxide in refractory acute myeloid leukemia other than acute promyelocytic leukemia,” Blood, 94:4230a (1999).
Goyer, “Toxic effects of metals” InCasarett and Doull's Toxicology: The Basic Science of Poisons, 5th edition. C.D. Klassen, ed. McGraw-Hill: New York, pp. 691-698 (1996).
Grignani, et al., “The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells,” Cell, 74:423-431 (1993).
Hosain, et al., “Synthesis of radioarsenic labeled dimethylchloroarsine for derivation of a new group of radiopharmceuticals,” International Journal of Applied Radiation and Isotopes, 33(12):1477-1478 (1982).
Hughes and Kenyon, “Dose-dependent effects on the disposition of monomethylarsonic acid and dimethylarsinic acid in the mouse after intravenous administration,” J. Toxicol. Environ. Health, 53(2):95-112 (1998).
Iarc. Some metals and metallic compounds. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man. vol. 23:39-141 (1980).
Ionov, et al., “Reaction of tertiary arsine sulfides with alkyl chlorocarbonates,” Zhurnal Obshchei Khimii, 46(11):2555-2558 (1976).
Kala, et al., “The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for bilary excretion of arsenic,” J. Biol. Chem., 275(43):33404-33408 (2000).
King and Ludford, “Relation between the constitution of arsenicals and their action on cell division,” Journal of the Chemical Society Abstracts, 2086-2088 (1950).
Kitamura, et al., “New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation,” Cancer Chemother Pharmacol., 40 (Suppl):S36-S41 (1997).
Knock, et al., “The use of selected sulfhydryl inhibitors in a preferential drug attack on cancer,” Surg. Gynecol. Obstet., 133:458-466 (1971).
Konig, A., et al., “Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines,” Blood 90:562-570 (1997).
Lallemand-Breitenback, et al., “Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia,” J. Exp. Med., 189:1043-1052 (1999).
Lam, et al., “Spectroscopic studies of arsenic (III) binding toEscherichia coliRI methyltransferase and to two mutants, C223S and W183F,” Biochemistry, 31(43):10438-10442 (1992).
Lin, et al., “Methylarsenicals and arsinothiols are potent inhibitors of mouse liver thioredoxin reductase,” Chemical Research in Toxicology, 12(10):924-930 (1999).
Mountain, et al., “Chemotherapy studies in an animal tumor spectrum: II. Sensitivity of tumors to fourteen antitumor chemicals,” Cancer Res., 26:181-206 (1966).
Rivi, et al., “Organic arsenical melarsoprol shows growth suppressive activity via programmed cell death on myeloid and lymphoid leukemia derived cell lines,” Blood (Suppl), 88:68a (1996).
Rousselot, et al., “Use of arsenic trioxide (As2O3) in the treatment of chronic myelogenous leukemia: In vitro and in vivo studies,” Blood, 94:4457a (1999).
Schoene, et al, “Speciation of arsenic-containing chemical warfare agents by gas chromatographic analysis after derivatization with thiogicolic acid methyl ester,” Journal of Chromatography, 605(2):257-262 (1992).
Scott, et al., “Reactions of arsenic (III) and arsenic (V) species with glutathione,” Chemical Research in Toxicology, 6(1):102-106 (1993).
Soignet, et al., “Clinical study of an organic arsenic melarsoprol, in patients with advanced leukemia,” Cancer Chemother. Pharmacol. 44:417-421 (1999).
Soignet, et al., “Dose-ranging and clinical pharmacologic study of arsenic trioxide in patients with advanced hematologic cancers,” Blood, 94:1247a (1999).
Styblo, et al., “Comparative inhibition of yeast glutathione reductase by arsenicals and arsenothiols,” Chemical Research in Toxicology, 10(1):27-33 (1997).
Tallman, “Therapy of acute promyelocytic leukemia: all-tans retinoic acid and beyond,” Leukemia, 12 (Suppl 1):S37-S40 (1998).
Tsalev, et al., “Flow-Injection hydride generation atomic absorption spectrometric study of the automated on-line pre-reduction of arsenate, methylarsonate and dimethylarsinate and high-performance liquid chromatographic separation of their 1-cysteine complexes,” Talanta, 51(6):1059-1068 (2000).
Wiernik, et al., “Phase II trial of arsenic trioxide (As2O3) in patients with relapsed/refractory acute myeloid leukemia, blast crisis of CML or myelodysplasia,” Blood, 94:2283a (1999).
Zhang, et al., “Arsenic trioxide treated 72 cases of acute promyelocytic leukemia,” Chin. J. Hematol., 17:58-62 (1996).
Cullen, et al., “The reaction of methylarsenicals with thiols: some biological implications,” Journal of Inorganic Biochemistry, 21(3):179-194 (1984).
Vega, et al., &
Duzkale Hatice
Freireich Emil J.
Gao Mingzhang
Kantarjian Hagop
Sotelo-Lerma Merida
Board of Regents , The University of Texas System
Gonzale Porfirio Nazario
Ropes & Gray LLP
The Texas A&M University System
LandOfFree
Compounds and methods for the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for the treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2754647